Ampicillin Plus Ceftriaxone Is as Effective as Ampicillin Plus Gentamicin for Treating Enterococcus faecalis Infective Endocarditis
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The aim of this study was to compare the effectiveness of the ampicillin plus ceftriaxone (AC) and ampicillin plus gentamicin (AG) combinations for treating Enterococcus faecalis infective endocarditis (EFIE). METHODS: An observational, nonrandomized, comparative multicenter cohort study was conducted at 17 Spanish and 1 Italian hospitals. Consecutive adult patients diagnosed of EFIE were included. Outcome measurements were death during treatment and at 3 months of follow-up, adverse events requiring treatment withdrawal, treatment failure requiring a change of antimicrobials, and relapse. RESULTS: A larger percentage of AC-treated patients (n = 159) had previous chronic renal failure than AG-treated patients (n = 87) (33% vs 16%, P = .004), and AC patients had a higher incidence of cancer (18% vs 7%, P = .015), transplantation (6% vs 0%, P = .040), and healthcare-acquired infection (59% vs 40%, P = .006). Between AC and AG-treated EFIE patients, there were no differences in mortality while on antimicrobial treatment (22% vs 21%, P = .81) or at 3-month follow-up (8% vs 7%, P = .72), in treatment failure requiring a change in antimicrobials (1% vs 2%, P = .54), or in relapses (3% vs 4%, P = .67). However, interruption of antibiotic treatment due to adverse events was much more frequent in AG-treated patients than in those receiving AC (25% vs 1%, P < .001), mainly due to new renal failure (≥25% increase in baseline creatinine concentration; 23% vs 0%, P < .001). CONCLUSIONS: AC appears as effective as AG for treating EFIE patients and can be used with virtually no risk of renal failure and regardless of the high-level aminoglycoside resistance status of E. faecalis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the study by Fernández-Hidalgo et al, 191 26% of the 272 patients had high-level aminoglycoside-resistant strains of E faecalis.”
In the citing paper
“Sixth, in the larger study, there were no significant differences between ampicillin-ceftriaxone and ampicillin-gentamicin in the need for surgery, complications (except for fewer cases of renal failure in the ampicillin-ceftriaxone group), relapse, or mortality.”
In the citing paper
“Second, high-level aminoglycoside-resistant E faecalis IE treated with ampicillin-ceftriaxone therapy was present in 50% of the patients in the smaller study and 33% of patients in the larger study.”
In the citing paper
“Fourth, in the larger study, the median age was 70 years in both treatment groups; however, patients in the ampicillin-ceftriaxone group were generally sicker and had more comorbid conditions (eg, chronic renal failure [P=0.004],neoplasm [P=0.015], and nosocomial acquisition of infection [P=0.006]).”
In the citing paper
“First, these are the largest series of E faecalis IE reported to date, 43 patients in 1 study 190 and 272 in the other study.191”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027 · cited 1×
“Definitions IE was defined as definite or possible according to the modified Duke criteria [10].”
MethodMurdoch, D. R. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.603 · Cited by 2,362
Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009)
Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and by the International Society of Chemotherapy (ISC) for Infection and Cancer, Habib, G., Hoen, B., Tornos, P., Thuny, F., Prendergast, B., Vilacosta, I., Moreillon, P., de Jesus Antunes, M., Thilen, U., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp285 · Cited by 2,014
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Preeminence of Staphylococcus aureus in Infective Endocarditis: A 1-Year Population-Based Survey
Selton-Suty, C., Célard, M., Le Moing, V., Doco-Lecompte, T., Chirouze, C., Iung, B., Strady, C., Revest, M., Vandenesch, F., Bouvet, A., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis199 · Cited by 710
Intravascular catheter-related infections: advances in diagnosis, prevention, and management
Raad, I., Hanna, H., & Maki, D. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70235-9 · Cited by 525 · cited 1×
“Healthcare-associated IE [11] and catheter-related bacteremia [12] have been defined elsewhere.”
BackgroundContemporary Epidemiology and Prognosis of Health Care–Associated Infective Endocarditis
Fernández‐Hidalgo, N., Almirante, B., Tornos, P., Pigrau, C., Sambola, A., Igual, A., & Pahissa, A. (2008) · Clinical Infectious Diseases · doi:10.1086/592576 · Cited by 217
Self-citationGavaldà, J., Len, O., Miró, J. M., Muñoz, P., Montejo, M., Alarcón, A., de la Torre-Cisneros, J., Peña, C., Martínez-Lacasa, X., Sarria, C., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00008 · Cited by 202 · cited 3×
“Since the publication of an observational, nonrandomized, multicenter clinical trial in 2007 [9], the ampicillin plus ceftriaxone (AC) combination has been recognized as a viable alternative for treating E.”
BackgroundSelf-citationMcDonald, J. R., Olaison, L., Anderson, D. J., Hoen, B., Miro, J. M., Eykyn, S., Abrutyn, E., Fowler, V. G., Habib, G., Selton-Suty, C., et al. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.02.020 · Cited by 170
Cited by
Items 201–300 of 346
Enterococcal Infections in Adults
Reyes, K., Zervos, M., & John, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_3 · Cited by 5
Antimicrobial Treatment of Infective Endocarditis, Caused by Enterococcus Faecalis
Ших, Е. В., Морозова, Т. Е., Drozdov, V. N., Lazareva, N. B., Андреевич, Ш. Д., Андрущишина, Т. Б., Лукина, М. В., & Вартанова, О. А. (2019) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2019-15-4-586-592 · Cited by 5
Acute Kidney Injury After Nephrotoxic Antibiotic Therapy in Patients with Infective Endocarditis
Sadeghpour, A., Boudagh, S., Ghadrdoost, B., Futuhi, F., Alizadehasl, A., Moradnejad, P., Kamali, M., Pasha, H. R., & Maleki, M. (2019) · Archives of Clinical Infectious Diseases · doi:10.5812/archcid.87617 · Cited by 5
Antibiotic-resistant bacteria in wastewater and potential human exposure through wastewater reuse
Goldstein, R. E. R. (2013) · University Libraries (University of Maryland) · Cited by 5
Combination Therapy for Enterococcal Endocarditis
Gelfand, M. S., & Cleveland, K. O. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit338 · Cited by 5
Outpatient Parenteral Antibiotic Treatment for Infective Endocarditis: Insights From Real Life
Tattevin, P., & Revest, M. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz027 · Cited by 5
Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?
Munita, J. M., & Tamma, P. D. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00121-25 · Cited by 5
Seki, M. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s539674 · Cited by 4
“26 In principle, anti-MRSA drugs should be used alone, but the efficacy of VCM, teicoplanin (TEIC), arbekacin (ABK), and daptomycin (DAP) in combination with β-lactams has been demonstrated in vitro and in vivo for MRSA infections with mixed infections, while further studies are needed to determine…”
Monotherapy vs. combination therapy for Enterococcus faecalis bacteraemia: a target trial emulation
Bartoletti, M., Turco, E. R. D., Bussini, L., Paul, M., Sabik, E. F., Castagna, A., Ripa, M., Gomes, M. Z. R., Bella, S. D., Malosso, M., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.03.018 · Cited by 4
Schubert, L., Chen, R., Weiss-Tessbach, M., Kriz, R., Obermüller, M., Jackwerth, M., Barousch, W., Burgmann, H., Kussmann, M., & Traby, L. (2024) · Infection · doi:10.1007/s15010-024-02407-6 · Cited by 4
Traitement de l’endocardite infectieuse
Hoen, B., Elfarra, M., Huttin, O., Goehringer, F., Venner, C., & Selton‐Suty, C. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.04.015 · Cited by 4
Enterococcus hirae Mitral Valve Infectious Endocarditis: A Case Report and Review of the Literature
Gaudiano, R., Trizzino, M., Torre, S., Virruso, R., Fiorino, F., Argano, V., & Cascio, A. (2023) · Antibiotics · doi:10.3390/antibiotics12081232 · Cited by 4
“hirae IE, reducing the risk of renal failure, which is typically associated with gentamicin administration [18].”
BackgroundSugiyama, K., Hirai, K., Suyama, Y., & Tsutsumi, M. (2024) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-024-00360-y · Cited by 4
Briggs, S. E., Duffy, E., Bhally, H. S., Broom, M. T., Campbell, P. O., Lane, R. J., McBride, S., Walls, G. B., & Dalton, S. C. (2024) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae168 · Cited by 4
Tran, T. T., Tam, V. H., Murray, B. E., Arias, C. A., & Singh, K. V. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02489-16 · Cited by 4
“Clinical data on the use of these regimens suggest that patients relapse in 3 to 5% of cases, and the use of aminoglycosides may be associated with renal toxicity requiring treatment withdrawal (26, 27).”
BackgroundPalraj, R., Knoll, B. M., Baddour, L. M., & Wilson, W. R. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00083-7 · Cited by 4
Vigneswaran, N., & McKew, G. L. (2022) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlac096 · Cited by 4
Khoury, A., & Rattanasuwan, T. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.endocarditis_overview · Cited by 4
Gregson, A., Mowlaboccus, S., Sudeep, S. M., Rizzo, S., Purani, J., Martínez, E., Coombs, G. W., Sandaradura, I., & McKew, G. L. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf377 · Cited by 3
Rejuvenating aminoglycosides usage in geriatric patients with gram-negative infections
Pagani, L. (2014) · European Geriatric Medicine · doi:10.1016/j.eurger.2014.01.006 · Cited by 3
“Moreover, some relevant experiences have recently opened a thorough appraisal of aminoglycoside usage in enterococcal endocarditis [7–11].”
BackgroundAmoxicillin and Ceftriaxone: A Synergistic Association Against Listeria monocytogenes
Sixt, T., Moretto, F., Neves, S. D., Amoureux, L., Neuwirth, C., Piroth, L., Blot, M., Chavanet, P., & Bador, J. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae295 · Cited by 3
“Yet, the association of AMX with a third-generation cephalosporins (ceftriaxone [CTR]) has shown its synergistic action in vitro and in vivo [7, 8] against Enterococcus faecalis and is now recommended for the management of infectious endocarditis as an alternative to the classic association…”
BackgroundGilbert, Z., Markovic, J., & Stultz, D. (2021) · Cureus · doi:10.7759/cureus.19716 · Cited by 3
“A combination of ampicillin plus ceftriaxone has been found to be an effective alternative [8-9].”
BackgroundWhich trial do we need? Elective early surgical treatment of left-sided infective endocarditis
Fernández‐Ruiz, M., & Aguado, J. M. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.04.010 · Cited by 3
Villamarín, M., Fernández‐Hidalgo, N., Viñado, B., González‐López, J. J., Rello, P., & Escolà‐Vergé, L. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae291 · Cited by 3
Self-citationEfficacy of Omadacycline against Escherichia coli in a Mouse Urinary Tract Infection Model
Singh, K. V., & Murray, B. E. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00269-21 · Cited by 3
“Similarly, aminoglycosides like GEN, although often active, may result in acute kidney injury (17).”
BackgroundMoreira, N. B., Nastro, M., Vay, C. A., Famiglietti, A. M. R., & Rodríguez, C. H. (2016) · Revista Argentina de Microbiología · doi:10.1016/j.ram.2015.11.004 · Cited by 3
Daptomycin and Ampicillin Combination for Treatment of Enterococcus faecalis Endocarditis
Sierra‐Hoffman, M., Iznaola, O., Lamp, K. C., Mohr, J., & Winn, R. E. (2015) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000000282 · Cited by 3
General principles of antimicrobial therapy for infective endocarditis
Данилов, А. И., & Kozlov, S. N. (2019) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2019-2-57-60 · Cited by 3
Infective endocarditis presenting as diffuse alveolar hemorrhage: A case report
Morita, M., & Tomioka, H. (2019) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2019.100931 · Cited by 3
Solla, D. J. F. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit340 · Cited by 3
“I read with interest the article by Fernández-Hidalgo et al, comparing the effectiveness of the ampicillin plus ceftriaxone (AC) and ampicillin plus gentamicin (AG) combinations for treating Enterococcus faecalis infective endocarditis (EFIE) [1].”
InfluentialEnterococcus - Unveiling the Emergence of a Potent Pathogen
Téllez‐Isaías, G., Graham, D. L., & El-Ashram, S. A. (2024) · Infectious diseases · doi:10.5772/intechopen.114606 · Cited by 2
Samani, R. J., Tajbakhsh, E., Momtaz, H., & Samani, M. K. (2024) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v23i3.8 · Cited by 2
Funk, O. G., Li, J., Khan, I., & Cusumano, J. A. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01050-25 · Cited by 2
The Evolving Landscape of Infective Endocarditis: Past, Present, and Future
LAU, L. S. W., Xing, L., Baddour, L. M., Chan, V., & Messika–Zeitoun, D. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.12.009 · Cited by 2
Sunnerhagen, T., Bjarnsholt, T., Qvortrup, K., Bundgaard, H., & Moser, C. E. (2024) · Biofilm · doi:10.1016/j.bioflm.2024.100236 · Cited by 2
Infective endocarditis in 2018
Pelouch, R. (2018) · Intervenční a akutní kardiologie · doi:10.36290/kar.2018.041 · Cited by 2
Chaudhary, J., Singh, N., Srivastava, V. K., Jyoti, A., & Kaushik, S. (2022) · Vegetos · doi:10.1007/s42535-022-00485-1 · Cited by 2
Guidance for Implementing an Antimicrobial Stewardship Program in Japan -Revised edition-
8学会合同抗微生物薬適正使用推進検討委員会, 公. (2025) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.as2025 · Cited by 3
Chen, J., Zhang, L., Wang, Y., Cui, S., Liang, Z., & Xu, L. T. (2025) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2025.3614299 · Cited by 2
“Resistance mechanisms may involve alterations in cell wall composition or target sites [49].”
A Clinician’s Guide to the Treatment of Vancomycin Resistant Enterococci Bacteremia and Endocarditis
Soule, D., & Climo, M. W. (2016) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-016-0082-8 · Cited by 2
Effect Oral Administration Ampicillin on the Ecological Balance of rat Enterococcal gut Microbiota
Benabbou, T. A., Zadi-Karam, H., & Nour-Eddine, K. (2019) · Current Microbiology · doi:10.1007/s00284-019-01635-6 · Cited by 2
Jent, P., Thalmann, L., Pabst, T., Droz, S., & Sendi, P. (2019) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2019.1581946 · Cited by 2
Mahmoud, E., Abanamy, R., Bosaeed, M., & Elsherif, Z. T. (2020) · IDCases · doi:10.1016/j.idcr.2020.e00726 · Cited by 2
“In our case, the relapse of bacteremia occurred after 30 days of completing the treatment course of 6 weeks of ampicillin and ceftriaxone, which is close to the reported time in one retrospective cohort (46-120-21-42 days, a mean of 57 days) [8], while the median was 37 days in the retrospective cohort comparing ampic…”
ResultReply to Gelfand et al and Solla
Fernández‐Hidalgo, N., Almirante, B., & Pahissa, A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit331 · Cited by 2
“faecalis strains in our study presented high-level aminoglycoside resistance [2], it is difficult not to support the use of AC as the first therapeutic option.”
BackgroundSelf-citationSpecial Issue: “Current Trends and Outcomes of Infective Endocarditis”
Ιωάννου, Π., & Kofteridis, D. P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12154935 · Cited by 2
Case Commentary: Dual β-lactam as part of regimen to treat Mycobacterium abscessus lung disease
Lippincott, C. K., & Lamichhane, G. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00585-24 · Cited by 2
Prognosis and Follow-Up in Infective Endocarditis
Harb, S. C., & Hassan, O. K. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65839-6_35 · Cited by 1
Rando, E., Rodríguez‐Baño, J., & López-Cortés, L. E. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.03.020 · Cited by 1
Antibacterial Therapeutic Agents
Stimes, G. T., & Palazzi, D. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00252-1 · Cited by 1
Worrasan, A., Pongchaidecha, M., & Santimaleeworagun, W. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-12993-5 · Cited by 1
Patient characteristics and prognostic importance of dialysis in IE—A nationwide study
Petersen, J. K., Østergaard, L., Graversen, P. L., Hadji-Turdeghal, K., Stahl, A., Alhakak, A., Møller, J. E., Bruun, N. E., Povlsen, J. A., Moser, C. E., et al. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107435 · Cited by 1
Infective Endocarditis: A Contemporary Review of Epidemiology, Diagnosis, and Management
Ishak, A., Qadeer, Y. K., AlRawashdeh, M. M., Yue, B., Khawaja, M., Strauß, M., & Krittanawong, C. (2026) · Antibiotics · doi:10.3390/antibiotics15050482 · Cited by 2
Ståhl, A., Østergaard, L., Hadji-Turdeghal, K., Graversen, P. L., Knudsen, I. H. J., Sørensen, L. M., Dahl, A., Møller, J. E., Bruun, N. E., Povlsen, J. A., et al. (2026) · Infection · doi:10.1007/s15010-026-02974-w · Cited by 1
Enterococcal Diskitis: Case Reports and Review of Reported Patients
Gavriel, G., Kory, R., Rajbi, H., Weil‐Weiner, Y., Yinnon, A. M., & Sylvetsky, N. (2014) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000000185 · Cited by 1
Haslam, D. B., & Geme, J. W. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40181-4.00120-1 · Cited by 1
Follow guidance to individualize antibacterial regimens when treating infective endocarditis
Writers, A. M. (2013) · Drugs & Therapy Perspectives · doi:10.1007/s40267-013-0099-8 · Cited by 1
“faecalis (in mortality, treatment failure and relapse rates), but with a lower rate of new renal failure [10]”
BackgroundNouvelles associations dans le traitement des infections graves à cocci à Gram positif
Fernandez‐Gerlinger, M., & Mainardi, J. (2014) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2014.01.003 · Cited by 1
Treating endocarditis: A protocol of an antimicrobal treatment from a middle-income country
Barbosa, G. F., Zappa, B. C., Garrido, R. Q., & Lamas, C. D. C. (2018) · Heart Vessels and Transplantation · doi:10.24969/hvt.2018.65 · Cited by 1
Drug Dosing in Acute Kidney Injury
DeGrado, J. R., Gilmore, J. F., Hohlfelder, B., Stevens, C. A., & Gabardi, S. (2018) · Springer eBooks · doi:10.1007/978-1-4939-8628-6_23 · Cited by 1
Ponomareva, E. Y. (2016) · Clinical Medicine (Russian Journal) · doi:10.18821/0023-2149-2016-94-9-662-668 · Cited by 1
Wichtige Antibiotikaindikationen und Krankheitsbilder unter ASB-Gesichtspunkten
Schulz-Stübner, S. (2020) · Springer eBooks · doi:10.1007/978-3-662-60558-5_11 · Cited by 1
Les endocardites à entérocoques : état des connaissances et perspectives
Danneels, P., & Dubée, V. (2023) · Médecine et Maladies Infectieuses Formation · doi:10.1016/j.mmifmc.2023.03.380 · Cited by 1
Santos, C. A. Q., Tseng, M., Martinez, A. I., Shankaran, S., Hodgson, H. A., Ahmad, F. S., Zhang, H., Sievert, D. M., & Trick, W. E. (2023) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2023.180 · Cited by 1
Tong, K., Luo, H., Dai, H., & Huang, W. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s448612 · Cited by 1
Ishikawa, K., Kobayashi, D., & Mori, N. (2024) · Antibiotics · doi:10.3390/antibiotics13080696 · Cited by 1
Seltene Nebenwirkung bei Therapie einer bakteriellen Endokarditis
George, C., Gisler, F., & Flückiger, U. M. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2505-8860 · Cited by 1
Prosthetic Valve Endocarditis and Cardiovascular Device Related Infections
Remington, T. L., & Doucette, K. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-27784-4_11 · Cited by 1
“faecalis IE demonstrated similar mortality rates between patients treated with ceftriaxone and ampicillin compared to those treated with ampicillin and gentamicin; 35 % of the patients in the study had PVIE [ 35 ].”
ResultBeganovic, M., Luther, M. K., Rice, L. B., Arias, C. A., Rybak, M. J., & LaPlante, K. L. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz057 · Cited by 1
Lecomte, R., Issa, N., Camou, F., & Boutoille, D. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa264 · Cited by 1
Enterococcal Endocarditis: The Eternal Return of the Same Bug
Pericàs, J. M., Llopis, J., Ramos, A., Fernández‐Cruz, A., Muñóz, P., & Miró, J. M. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa263 · Cited by 1
Dean, Z. (2019) · Deep Blue (University of Michigan) · doi:10.13140/rg.2.2.29108.50560 · Cited by 1
GENÇ, B. O. (2018) · Dspace Repository (Marmara Üniversitesi) · Cited by 1
Wasselin, V. (2022) · theses.fr (ABES) · doi:10.70675/88eabc79z4b3bz44c5zb803z30dec7989e8b · Cited by 1
Estado actual de la endocarditis enterocócica. Retos de futuro
Escolà‐Vergé, L., & de Medicina, U. A. D. B. D. (2020) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Miscellaneous Antibacterial Drugs
Burr, L. D., Cunningham, J., & Serisier, D. J. (2014) · Side effects of drugs annual · doi:10.1016/b978-0-444-63407-8.00026-5
Rigor in the Design of Observational Noninferiority Trials
DiNubile, M. J. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit386
Antibiothérapie des endocardites infectieuses à enterocoques
François, M. (2014)
Ampicillin plus Ceftriaxone for
Ampel, N. M. (2013) · Journal watch · doi:10.1056/id201304100000004
New Guidelines Endorse Old Recommendations for Invasive Enterococcal Infections
Werth, B. J., Smith, J. R., & Sakoulas, G. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw286
Aminoglycosides for Surgically Treated Enterococcal Endocarditis
Banzon, J. M., Hussain, S. T., Gordon, S. M., Pettersson, G., Butler, R. S., & Shrestha, N. K. M. (2016) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2016.04.018
Lennon, C. M., Fort, A. C., & Hansberry, S. (2015) · Advances in medical technologies and clinical practice book series · doi:10.4018/978-1-4666-8603-8.ch008
Ouamri, M. (2016)
Advances in the Diagnosis and Treatment of Infective Endocarditis
Turner, R. B., & Schwartz, J. (2017) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-2092-4.ch010
Relevancia de la fibrilación auricular en la endocarditis infecciosa
Durán, C. F. (2015) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Chen, C.-L. (2016) · Purdue e-Pubs (Purdue University System)
Endocarditis infecciosa a principis del segle XXI: nous reptes
Fernández‐Hidalgo, N. (2013) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Self-citationCahill, T. J., & Prendergast, B. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.057
Thalhammer, F., Apfalter, P., Frick, M. V., Gabriel, H., Gattringer, R., Grisold, A. J., Krause, R., Loewe, C., H-J, N., Müller, L. C. C. M., et al. (2017) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Díaz, A. M. S. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Plata, A. (2016) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Self-citation[Hormone replacement therapy and cancer risk].
Matsushita, H., & Wakatsuki, A. (2012) · PubMed
New possibilities for the treatment of enterococcal infectious endocarditis
Tyurin, V. P., Григорьевич, Г. В., Volkova, L. V., Gvozdkov, A. L., Zharkov, O. B., Жирова, Л. Г., Мезенова, Т. В., & Гусаим, Т. А. (2016) · Clinical Medicine (Russian Journal) · doi:10.18821/10/18821/0023-2149-2016-94-4-255-259
Endocarditis: Osler’s Challenge
Long, B., & Koyfman, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-22445-5_19
Pizzi, M. N. (2019) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
You Can't Use that Drug… or Can You?
Bryson, A. L., & Doern, C. D. (2020) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2020.08.002
Artificial sweeteners negatively impact gut epithelium and microflora
Shil, A. (2020) · Anglia Ruskin Research Online (Anglia Ruskin University)
Westbrook, K. J., Chilambi, G. S., Nordstrom, H. R., Iovleva, A., Shah, N. H., Jones, C. E., Kline, E. G., Doi, Y., Shields, R. K., & Tyne, D. V. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.07.447474
“faecalis IE 46 with AC is as efficacious as treatment with AG, and results in lower rates of renal 47 toxicity (16, 17).”
BackgroundMethodWichtige Antibiotikaindikationen und Krankheitsbilder unter ASB-Gesichtspunkten
Schulz-Stübner, S. (2020) · Springer eBooks · doi:10.1007/978-3-662-60560-8_11
Hitzenbichler, F. (2023) · Elsevier eBooks · doi:10.1016/b978-3-437-23817-8.00008-2
Other Gram-Positive Infections
Tatara, A. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-39474-4_3
Metadata
- Authors
- Fernández-Hidalgo, N., Almirante, B., Gavaldà, J., Gurgui, M., Peña, C., de Alarcón, A., Ruiz, J., Vilacosta, I., Montejo, M., Vallejo, N., López-Medrano, F., Plata, A., López, J., Hidalgo-Tenorio, C., Gálvez, J., Sáez, C., Lomas, J. M., Falcone, M., de la Torre, J., Martínez-Lacasa, X., & Pahissa, A.
- Affiliations
- Vall d'Hebron Hospital Universitari (ES)
- Bellvitge University Hospital (ES)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Hospital Clínico San Carlos (ES)
- Hospital de Cruces (ES)
- Hospital Clínico Universitario de Valladolid (ES)
- Hospital Universitario Virgen de las Nieves (ES)
- Hospital Universitario de La Princesa (ES)
- Hospital Juan Ramón Jiménez (ES)
- Policlinico Umberto I (IT)
- University Hospital Mútua de Terrassa (ES)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-07
- Volume
- 56
- Issue
- 9
- Pages
- 1261-1268
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2137285136
- Semantic Scholar
- 9646599067b0e52124c95b08e69a38b3bd9e8a91
- Cited by
- 311
- References
- 22
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 25 · 2023: 23 · 2022: 16 · 2021: 19 · 2020: 26 · 2019: 35 · 2018: 21 · 2017: 21 · 2016: 23 · 2015: 26 · 2014: 16 · 2013: 19
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- Enterococcus faecalis, infective endocarditis, ampicillin, ceftriaxone, gentamicin, combination antibiotic therapy, aminoglycoside resistance, renal failure, treatment failure, relapse, mortality, adverse drug reactions
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Ampicillin, Anti-Bacterial Agents, Ceftriaxone, Drug Therapy, Combination, Endocarditis, Female, Gentamicins, Hospitals, Humans, Italy, Male, Middle Aged, Spain, Enterococcus faecalis, Cohort Studies, Treatment Outcome, Gram-Positive Bacterial Infections, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.